ESCC

23 registered clinical trials studyying ESCC — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitax NCT07493993	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Not Yet Recruiting	Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or M NCT07533305	The First Affiliated Hospital of Henan University of Science and Technology	Phase 2
Not Yet Recruiting	Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophag NCT07531979	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Not Yet Recruiting	SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy NCT07524374	Zhigang Li	Phase 2
Not Yet Recruiting	Adebrelimab Neoadjuvant Treatment for Resectable ESCC NCT07388095	Tianjin Medical University Cancer Institute and Hospital	N/A
Recruiting	A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149	Normunity AccelCo, Inc.	Phase 1
Not Yet Recruiting	TAS-102 Plus Radiotherapy in Elderly ESCC NCT07196345	Qianfoshan Hospital	Phase 1 / Phase 2
Completed	Development and Multicenter Validation of a Novel Bio-Anatomical Staging System for Predicting Survival and Ta NCT07488624	Sichuan University	—
Recruiting	A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors NCT07085091	ALX Oncology Inc.	Phase 1
Recruiting	Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell NCT06764355	National Taiwan University Hospital	Phase 2
Recruiting	Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma NCT07266363	City of Hope Medical Center	—
Recruiting	AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Pa NCT06489197	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Not Yet Recruiting	Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumo NCT06531291	RenJi Hospital	Phase 2
Recruiting	Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma NCT07050576	The First Affiliated Hospital of Anhui Medical University	—
Recruiting	Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carci NCT06698692	The First Affiliated Hospital with Nanjing Medical University	—
Unknown	Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With St NCT05547828	The First Affiliated Hospital of Xinxiang Medical College	Phase 2
Completed	Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer NCT07015489	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Terminated	Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants NCT04939701	Astellas Pharma Global Development, Inc.	Phase 1 / Phase 2
Unknown	DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer NCT05050760	Xijing Hospital	N/A
Recruiting	A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682	Jacobio Pharmaceuticals Co., Ltd.	Phase 1 / Phase 2
Unknown	Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 ) NCT04863079	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Unknown	TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer NCT04471480	Dong Wang	N/A
Active Not Recruiting	Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（C NCT06478355	Hebei Medical University Fourth Hospital	N/A